Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.

Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S.

Arch Neurol. 2010 Oct;67(10):1187-94. doi: 10.1001/archneurol.2010.248.

2.

Imaging of pancreatic islet cells.

Arifin DR, Bulte JW.

Diabetes Metab Res Rev. 2011 Nov;27(8):761-6. doi: 10.1002/dmrr.1248. Review.

3.

Immunomodulation by transplanted human embryonic stem cell-derived oligodendroglial progenitors in experimental autoimmune encephalomyelitis.

Kim H, Walczak P, Kerr C, Galpoththawela C, Gilad AA, Muja N, Bulte JW.

Stem Cells. 2012 Dec;30(12):2820-9. doi: 10.1002/stem.1218.

4.

Tracking stem cells using magnetic nanoparticles.

Cromer Berman SM, Walczak P, Bulte JW.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011 Jul-Aug;3(4):343-55. doi: 10.1002/wnan.140. Epub 2011 Apr 5. Review.

5.

X-ray-visible microcapsules containing mesenchymal stem cells improve hind limb perfusion in a rabbit model of peripheral arterial disease.

Kedziorek DA, Hofmann LV, Fu Y, Gilson WD, Cosby KM, Kohl B, Barnett BP, Simons BW, Walczak P, Bulte JW, Gabrielson K, Kraitchman DL.

Stem Cells. 2012 Jun;30(6):1286-96. doi: 10.1002/stem.1096.

6.

Personalized nanomedicine advancements for stem cell tracking.

Janowski M, Bulte JW, Walczak P.

Adv Drug Deliv Rev. 2012 Oct;64(13):1488-507. doi: 10.1016/j.addr.2012.07.008. Epub 2012 Jul 20. Review.

7.

Iron oxide MR contrast agents for molecular and cellular imaging.

Bulte JW, Kraitchman DL.

NMR Biomed. 2004 Nov;17(7):484-99. Review.

PMID:
15526347
8.
9.

ICV-transplanted human glial precursor cells are short-lived yet exert immunomodulatory effects in mice with EAE.

Kim H, Walczak P, Muja N, Campanelli JT, Bulte JW.

Glia. 2012 Jul;60(7):1117-29. doi: 10.1002/glia.22339. Epub 2012 Apr 12.

10.

Use of perfluorocarbon nanoparticles for non-invasive multimodal cell tracking of human pancreatic islets.

Barnett BP, Ruiz-Cabello J, Hota P, Ouwerkerk R, Shamblott MJ, Lauzon C, Walczak P, Gilson WD, Chacko VP, Kraitchman DL, Arepally A, Bulte JW.

Contrast Media Mol Imaging. 2011 Jul-Aug;6(4):251-9. doi: 10.1002/cmmi.424.

11.

Cell motility of neural stem cells is reduced after SPIO-labeling, which is mitigated after exocytosis.

Cromer Berman SM, Kshitiz, Wang CJ, Orukari I, Levchenko A, Bulte JW, Walczak P.

Magn Reson Med. 2013 Jan;69(1):255-62. doi: 10.1002/mrm.24216. Epub 2012 Feb 28.

12.

Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer.

Chan KW, McMahon MT, Kato Y, Liu G, Bulte JW, Bhujwalla ZM, Artemov D, van Zijl PC.

Magn Reson Med. 2012 Dec;68(6):1764-73. doi: 10.1002/mrm.24520. Epub 2012 Oct 16.

13.

Noninvasive monitoring of immunosuppressive drug efficacy to prevent rejection of intracerebral glial precursor allografts.

Gorelik M, Janowski M, Galpoththawela C, Rifkin R, Levy M, Lukomska B, Kerr DA, Bulte JW, Walczak P.

Cell Transplant. 2012;21(10):2149-57. doi: 10.3727/096368912X636911. Epub 2012 Apr 10.

PMID:
22508097
14.

Microcapsules with intrinsic barium radiopacity for immunoprotection and X-ray/CT imaging of pancreatic islet cells.

Arifin DR, Manek S, Call E, Arepally A, Bulte JW.

Biomaterials. 2012 Jun;33(18):4681-9. doi: 10.1016/j.biomaterials.2012.03.008. Epub 2012 Mar 22.

15.

Fluorine (19F) MRS and MRI in biomedicine.

Ruiz-Cabello J, Barnett BP, Bottomley PA, Bulte JW.

NMR Biomed. 2011 Feb;24(2):114-29. doi: 10.1002/nbm.1570. Epub 2010 Sep 15.

16.

In vivo MRI cell tracking: clinical studies.

Bulte JW.

AJR Am J Roentgenol. 2009 Aug;193(2):314-25. doi: 10.2214/AJR.09.3107. Review.

17.

Use of MR cell tracking to evaluate targeting of glial precursor cells to inflammatory tissue by exploiting the very late antigen-4 docking receptor.

Gorelik M, Orukari I, Wang J, Galpoththawela S, Kim H, Levy M, Gilad AA, Bar-Shir A, Kerr DA, Levchenko A, Bulte JW, Walczak P.

Radiology. 2012 Oct;265(1):175-85. Epub 2012 Aug 24.

18.

Imaging of cellular therapies.

Srinivas M, Aarntzen EH, Bulte JW, Oyen WJ, Heerschap A, de Vries IJ, Figdor CG.

Adv Drug Deliv Rev. 2010 Aug 30;62(11):1080-93. doi: 10.1016/j.addr.2010.08.009. Epub 2010 Aug 25. Review.

PMID:
20800081
19.

Neonatal desensitization does not universally prevent xenograft rejection.

Janowski M, Jablonska A, Kozlowska H, Orukari I, Bernard S, Bulte JW, Lukomska B, Walczak P.

Nat Methods. 2012 Sep;9(9):856-8; author reply 858. doi: 10.1038/nmeth.2146. No abstract available.

20.

Mesoporous silica-coated hollow manganese oxide nanoparticles as positive T1 contrast agents for labeling and MRI tracking of adipose-derived mesenchymal stem cells.

Kim T, Momin E, Choi J, Yuan K, Zaidi H, Kim J, Park M, Lee N, McMahon MT, Quinones-Hinojosa A, Bulte JW, Hyeon T, Gilad AA.

J Am Chem Soc. 2011 Mar 9;133(9):2955-61. doi: 10.1021/ja1084095. Epub 2011 Feb 11.

Supplemental Content

Support Center